MMSc MD - ImmunoGen VP Officer
Insider
MMSc MD is VP Officer of ImmunoGen
| Age | 54 |
| Phone | 781 895 0600 |
| Web | https://www.immunogen.com |
ImmunoGen Management Efficiency
The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoGen currently holds 15.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. ImmunoGen has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ImmunoGen's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith MD | X4 Pharmaceuticals | 54 | |
| Michael Esq | TG Therapeutics | 59 | |
| Stephen MD | Hepion Pharmaceuticals | N/A | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Alexandra HughesWilson | Mereo BioPharma Group | 54 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Kevin PharmD | Axsome Therapeutics | 46 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 64 | |
| MS MBA | Inozyme Pharma | 48 | |
| Jeff York | Seres Therapeutics | N/A | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Valerie MD | Elevation Oncology | 47 | |
| Launa Aspeslet | Hepion Pharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 61 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 |
ImmunoGen Leadership Team
Elected by the shareholders, the ImmunoGen's board of directors comprises two types of representatives: ImmunoGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoGen. The board's role is to monitor ImmunoGen's management team and ensure that shareholders' interests are well served. ImmunoGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, VP Officer | ||
| Susan Altschuller, VP CFO | ||
| MMSc MD, VP Officer | ||
| Lauren MBA, Senior Officer | ||
| Renee Lentini, VP Officer | ||
| Stacy Coen, Sr Officer | ||
| Audrey Bergan, Senior Officer | ||
| Courtney OKonek, Senior Relations | ||
| Isabel Kalofonos, Senior Officer | ||
| Anabel Chan, Head Relations | ||
| FACP MD, VP Affairs | ||
| Mark Enyedy, President CEO, Director | ||
| Theresa Wingrove, Vice President - Regulatory Affairs and Quality | ||
| Stacy MBA, Senior Officer |
ImmunoGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmunoGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X |
Pair Trading with ImmunoGen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ImmunoGen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ImmunoGen will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Fifth Third could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fifth Third when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fifth Third - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fifth Third Bancorp to buy it.
The correlation of Fifth Third is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fifth Third moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fifth Third Bancorp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fifth Third can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |